2′,2′-Difluorodeoxyuridine-13C,15N2

2′,2′-Difluorodeoxyuridine-13C,15N2 (dFdU-13C,15N2) is a 13C- and 15N-labeled compound. 2’,2’-Difluorodeoxyuridine (dFdU) is the main metabolite of Gemcitabine (HY-17026) . 2’,2’-Difluorodeoxyuridine causes a concentration- and schedule- dependent radiosensitising effect in vitro. 2’,2’-Difluorodeoxyuridine arrests cell cycle at the early S phase and induces apoptosis in cancer cells[1][2][3][4].

Product Specifications

CAS Number

[1233921-75-9]

Product Name Alternative

DFdU-13C,15N2; 2',2'-Difluoro-2'-deoxyuridine-13C,15N2

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Drug Metabolite; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Others

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/2-2-difluorodeoxyuridine-13c-15n2.html

Purity

99.50

Solubility

10 mM in DMSO

Smiles

O=[13C]([15NH]1)[15N]([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C=CC1=O

Molecular Formula

C8 13CH10F2 15N2O5

Molecular Weight

267.16

Precautions

H302, H315, H319, H335

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-246.|[2]Pauwels B, et al. The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemother Pharmacol. 2006 Aug;58 (2) :219-28. |[3]Veltkamp SA, et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. Mol Cancer Ther. 2008 Aug;7 (8) :2415-25.|[4]Veltkamp SA, et al. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. Drug Metab Dispos. 2008 Aug;36 (8) :1606-15.